Cytek Biosciences, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:CTKB) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 482.6 M493.32 M494.92 M461.54 M449.11 M Total liabilities 102.97 M115.76 M116.35 M119.8 M121.47 M Total equity 379.62 M377.56 M378.57 M341.74 M327.64 M Total liabilities & shareholders' equities 482.6 M493.32 M494.92 M461.54 M449.11 M Total debt ————— Net debt —————

News

Cytek Biosciences, Inc. (CTKB) Presents at Singular Research's Las Vegas Invitational Conference - Slideshow (NASDAQ:CTKB) 2026-06-15

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates

Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences earnings missed by $0.32, revenue topped estimates

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:CTKB) 2026-01-15

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth (CTKB)

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Beyond Meat (NASDAQ:BYND), Avadel Pharmaceuticals (NASDAQ:AVDL)

Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates